{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:48:08Z","timestamp":1761540488772,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":6920,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1111\/j.1538-7836.2004.00524.x","type":"journal-article","created":{"date-parts":[[2004,1,9]],"date-time":"2004-01-09T04:27:50Z","timestamp":1073622470000},"page":"77-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice"],"prefix":"10.1016","volume":"2","author":[{"given":"M.","family":"Dewerchin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Van Der Elst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grailly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u2010M.","family":"Saint\u2010Remy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Collen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jacquemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1657492","article-title":"Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis","volume":"78","author":"Rosendaal","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0015","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/00007611-200194100-00015","article-title":"Hypercoagulability: clinical assessment and treatment","volume":"94","author":"Abramson","year":"2001","journal-title":"South Med J"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0020","first-page":"757","article-title":"Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics","volume":"87","author":"Agnelli","year":"2002","journal-title":"Haematologica"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0025","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/bmj.325.7367.762","article-title":"ABC of antithrombotic therapy: an overview of antithrombotic therapy","volume":"325","author":"Blann","year":"2002","journal-title":"Br Med J"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-2007-994942","article-title":"Treatment of hereditary and acquired thrombophilic disorders","volume":"25","author":"Baker","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0035","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1001\/archinte.161.20.2433","article-title":"Hypercoagulability syndromes","volume":"161","author":"Thomas","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0040","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archinte.161.8.1051","article-title":"An update on hypercoagulable disorders","volume":"161","author":"Federman","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0045","first-page":"1","article-title":"Elevated plasma factor VIII levels\u2014a novel risk factor for venous thromboembolism","volume":"47","author":"O'Donnell","year":"2001","journal-title":"Clin Lab"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0050","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.ATV.21.5.731","article-title":"Elevated factor VIII levels and the risk of thrombosis","volume":"21","author":"Kamphuisen","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0055","first-page":"107","article-title":"Thrombosis: new culprits in an old disorder","volume":"44","author":"Federman","year":"2002","journal-title":"Panminerva Med"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0060","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1182\/blood.V99.9.3235","article-title":"Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model","volume":"99","author":"Singh","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0065","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1182\/blood.V93.7.2267","article-title":"Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A","volume":"93","author":"Peerlinck","year":"1999","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.V95.1.156","article-title":"A human antibody directed to the factor VIII, C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor","volume":"95","author":"Jacquemin","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0049-3848(83)90333-X","article-title":"Antithrombin III Toyama: a hereditary abnormal antithrombin III of a patient with recurrent thrombophlebitis","volume":"31","author":"Sakuragawa","year":"1983","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2141.1987.tb01301.x","article-title":"Comparative effect of heparin and heparan sulphate on two abnormal antithrombin III type 3 variants","volume":"66","author":"Fischer","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0085","doi-asserted-by":"crossref","unstructured":"Dewerchin M, H\u00e9rault P, Wallays G, Petitou M, Schaeffer P, Millet L, Weitz JI, Moons L, Collen D, Carmeliet P, Herbert JM. Life\u2010threatening thrombosis in mice with targeted Arg48\u2010to\u2010Cys mutation of the heparin binding domain of antithrombin. Circ Res 2003; 93: in press.","DOI":"10.1161\/01.RES.0000103634.69868.4F"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0268-960X(96)90034-X","article-title":"Molecular genetics of antithrombin deficiency","volume":"10","author":"Lane","year":"1996","journal-title":"Blood Rev"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0095","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00001721-199610000-00008","article-title":"Homozygous variant of antithrombin with lack of affinity for heparin: management of severe thrombotic complications associated with intrauterine fetal demise","volume":"7","author":"Bauters","year":"1996","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archpedi.1994.02170040055009","article-title":"Inherited antithrombin III deficiency in the neonate","volume":"148","author":"Seguin","year":"1994","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0037-1613783","article-title":"Blood coagulation Factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice","volume":"83","author":"Dewerchin","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0110","first-page":"612","article-title":"Proceedings: a more uniform measurement of factor VIII inhibitors","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/pcad.2002.127679","article-title":"The role of low\u2010molecular\u2010weight heparin in cardiovascular diseases","volume":"45","author":"Mukherjee","year":"2002","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0165-6147(00)01885-X","article-title":"Novel approaches to the treatment of thrombosis","volume":"23","author":"Gresele","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00063198-200209000-00010","article-title":"Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism","volume":"8","author":"Bauer","year":"2002","journal-title":"Curr Opin Pulm Med"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0130","first-page":"89","article-title":"Novel antithrombotics based on modulation of the protein C pathway","volume":"9","author":"Grinnell","year":"1998","journal-title":"Coron Artery Dis"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0049-3848(00)00299-1","article-title":"Comparing the antithrombotic efficacy of a humanized anti\u2010factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis","volume":"100","author":"Toomey","year":"2000","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0140","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/hs0202.102950","article-title":"Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke","volume":"33","author":"Toomey","year":"2002","journal-title":"Stroke"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0145","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0196-9781(00)00204-7","article-title":"Detailed characterization of an anti\u2010factor IX monoclonal antibody that neutralizes the prolonged ox brain prothrombin time of hemophilia B (M) by synthetic peptides","volume":"21","author":"Takahashi","year":"2000","journal-title":"Peptides"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0150","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1161\/01.ATV.19.10.2554","article-title":"Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats","volume":"19","author":"Feuerstein","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0155","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-0037-1615593","article-title":"Generation of a humanized, high affinity anti\u2010tissue factor antibody for use as a novel antithrombotic therapeutic","volume":"85","author":"Presta","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0160","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1055\/s-0037-1614173","article-title":"Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti\u2010tissue factor antibodies","volume":"84","author":"Kirchhofer","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2004.00524.x_bb0165","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/18877","article-title":"Synthesis of thrombin\u2010inhibiting heparin mimetics without side effects","volume":"398","author":"Petitou","year":"1999","journal-title":"Nature"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2004.00524.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622177871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622177871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2004.00524.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:28:38Z","timestamp":1761532118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622177871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S1538783622177871"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2004.00524.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2004,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2004.00524.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}